Patients waiting up to 48 hours to be seen in North Wales

The issue was raised at a social care and health scrutiny committee at Coed Pella, where councillors grilled Betsi Cadwaladr University Health Board chiefs on the state of the NHS in North Wales.
Attending the meeting were Dyfed Edwards, chair of the health board; Gareth Evans, integrated health community director; and Alison Cowell, assistant area director for child and adolescent health.
Mr Edwards began by acknowledging the challenges the board has faced since being placed in special measures two years ago.
He told councillors there had been 'challenges in every area' but claimed the situation had since stabilised. He also pointed to significant reductions in patient backlogs.
He said there had been a 43% reduction in the number of patients waiting two years or more for treatment.
MORE NEWS:
Health board looking at changing planning application review process
Park and Ride scheme could return to Glan Clwyd Hospital to ease parking woes
Woman 'outsourced and ostracised' after 10-month wait for Glan Clwyd scan results
Health chiefs added that a number of areas had improved, citing the example of Ysbyty Glan Clwyd's emergency department, which in 2022 been designated as a Service Requiring Significant Improvement (SRSI) due to concerns raised by the Healthcare Inspectorate Wales. It was de-escalated following an unannounced follow-up inspection of the Emergency Department in 2024.
LATEST NEWS:
'Large group of caravans' are found parked on private land in Rhuddlan
Rhyl bar opens with golf simulator, interactive darts and karaoke booth
Man ignored red light in Rhyl – now he's been handed a fine and points
But the claims were met with opposition from councillors, including Cllr Cheryl Carlisle, who questioned how the department could have been de-escalated while patient experiences remained 'worse than ever'.
She said: 'You say that Ysbyty Glan Clwyd (YGC), the emergency department (E.D) there, has been de-escalated by the Health Inspectorate for Wales, but the patient experience for those of us in Conwy is worse than ever.
'There are waits of 48 hours. I regularly witness my residents for 48 hours in chairs in corridors, and I'm not quite sure how de-escalation has come around, when things are patently so bad in this central area.'
Responding, Gareth Evans defended the board's progress, insisting some performance measures had improved, although he acknowledged major pressures remained.
He said: 'I don't think waits have got worse. I think, in some areas, performance data is telling us things have got a bit better.
'So things like how long people are waiting in ambulances before they are offloaded has actually got better; however, there are still some areas which probably haven't improved and probably are pretty much the same.
'So, we still have far too many people that wait more than 12 hours for admission once they need to be admitted. That is a key performance indicator that we are not getting worse on, but we are struggling to make the improvements that we would like to.
'And that is because that particular key performance measure is highly dependent on things that go on outside the emergency department – how long people are delayed getting home from hospital, and indeed, how many people are coming to the front door in the first place.
'So, I wouldn't want to play down the experience of people who use our services and our E.D. at YGC (who say it) still isn't good enough. It isn't. But the concerns that the Healthcare Inspectorate Wales identified when they placed us into special measures have been addressed.'
He added: 'But it doesn't mean it's perfect by any means. The problems we have at YGC E.D. are probably no different than the ones we have at E.D. departments anywhere in the UK, I would suggest.
'So there is lots, lots more improvement work going on, and we will need to go on so that hopefully, one day, you'll sit here and say things have got better.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Independent

26 minutes ago

• The Independent

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

South Wales Guardian

41 minutes ago

• South Wales Guardian

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Leader Live

an hour ago

• Leader Live

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.